We give a short comment on the recent FDA clearance for Nexstim’s partner Magnus Medical.

Redeye is encouraged by the continued momentum in Nexstim and path towards profitability, although with a somewhat new focus following the recent licensing agreement.

Redeye is cautiously optimistic to yesterday’s licensing agreement between Nexstim and Magnus Medical and gives an initial take.

Since our initiation of coverage, Nexstim has continued to deliver solid and higher-than-expected growth in its key segments of diagnostics and therapeutics.